For me the most interesting detail is to found on page 3 of the Forward by Paul N Jenner – it reads:
Section 3: Issues Management
This section will provide a synthesis of key facts and data which can be adapted locally for handling potential product issues. Topics covered in this first edition are:
• Managing the Discontinuation issue – flexibility and control
• Sexual dysfunction – putting the issue in context
I hope that one day we’ll be able to read Section 3 in full, but for now what we can be certain of is that (from at least 1998 – the publication date of this document) Glaxo has known that Seroxat/Paxil has a ‘Discontinuation issue’ that needs to be ‘managed’.
When Glaxo talks about ‘managing the discontinuation issue’ it does not mean helping patients who are suffering because of their drug, rather what they are talking about is hiding the truth so as to ensure it did not have a negative effect on sales levels.
This merely confirms what many of us have known for years – you can become addicted to Seroxat/Paxil and you can experience withdrawal problems if you try to stop taking the drug.
Very interesting that as long ago as 1998, Glaxo had identified that Seroxat/Paxil had a particular problem that set it aside from other SSRIs – withdrawal.
And the other issue to be ‘managed’…’Sexual dysfunction’? I am looking forward to seeing how they spun that one!!